From The Editor

  1. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

    Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

  2. Single-Use Standardization Starts At Home 8/28/2025

    During a Bioprocess Online Live event, “Single-Use Harmonization Needs A Tune Up," panelists discuss a way forward for the industry to unlock the true flexibility and promise of single-use technology.

  3. Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured 8/21/2025

    An element of the 2025 BioPlan Associates annual report and survey took Chief Editor Louis Garguilo by surprise. The report intimates that biopharmaceutical manufacturing faces a fractured CDMO market. Despite solid data to back that assertion up, Garguilo presents a very different view, one based on what many readers have expressed.

  4. Unlocking The Pharmacological Potential Of Antibodies 8/20/2025

    Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

  5. Tech Transfer 2025 – A High-Stakes Game Of Trust 8/4/2025

    Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.

  6. How Lumen Is Putting The "Farm" In Biopharma 7/31/2025

    Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.

  7. The Safety Potential Of Conditionally Active Biologics 7/28/2025

    Conditionally active biologics (CABs) are an emerging class of therapies that can reduce off-target toxicity in the clinic, and they were a topic of conversation at the 2025 BIO International Convention.

  8. CDMOs Should Stop Stringing Biotechs Along 7/28/2025

    Biotechs, first working closely with a CDMO’s sales manager, experience subsequent and sudden rejections of their projects. Did some of you just wince? If so, that might be because we are again hearing of a problem with sudden rejections after protracted discussions and even site visits. Part two on what is one of the biggest problems for outsourcing today.

  9. FDA Leading The Decline Of Animal Testing 7/16/2025

    The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).

  10. Governor Josh Shapiro On Supporting Biomanufacturing In Pennsylvania 7/15/2025

    Bioprocess Online's coverage of Governor Josh Shapiro’s fireside chat with BIO CEO, John Crowley, at the 2025 BIO International Convention.